Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Singh

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 21, 2024
Approval of the first TCR-based cell therapyNathan Singh
Hematology. American Society of Hematology. Education Program|December 10, 2021
Modified T cells as therapeutic agentsNathan Singh
Discovery Medicine|November 23, 2016
Recent advances in engineered T cell therapies targeting B cell malignanciesNathan Singh
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2024
Analysis of pre-treatment tumors reveals gatekeepers of response to CAR T cellsNathan Singh
Current Opinion in Hematology|October 13, 2015
Donor-derived CD19 chimeric antigen receptor T cellsNathan Singh, David M Barrett
Clinics in Chest Medicine|November 13, 2017
Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic MalignanciesNathan Singh, Alison W Loren
Immunity|October 11, 2023
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapyNathan Singh, Marcela V Maus
Cancer Cell|June 27, 2025
Disarming myeloid resistance in CAR T therapyJohn M Warrington, Nathan Singh
Science (New York, N.Y.)|July 13, 2019
Boosting engineered T cellsNathan Singh, Carl H June
The Lancet. Oncology|November 8, 2016
Vemurafenib for BRAF<sup>V600E</sup>-positive metastatic papillary thyroid cancer - Authors' responseMarcia S Brose, Nathan Singh
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 21, 2024
Approval of the first TCR-based cell therapyNathan Singh
Hematology. American Society of Hematology. Education Program|December 10, 2021
Modified T cells as therapeutic agentsNathan Singh
Discovery Medicine|November 23, 2016
Recent advances in engineered T cell therapies targeting B cell malignanciesNathan Singh
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2024
Analysis of pre-treatment tumors reveals gatekeepers of response to CAR T cellsNathan Singh
Current Opinion in Hematology|October 13, 2015
Donor-derived CD19 chimeric antigen receptor T cellsNathan Singh, David M Barrett
Clinics in Chest Medicine|November 13, 2017
Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic MalignanciesNathan Singh, Alison W Loren
Immunity|October 11, 2023
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapyNathan Singh, Marcela V Maus
Cancer Cell|June 27, 2025
Disarming myeloid resistance in CAR T therapyJohn M Warrington, Nathan Singh
Science (New York, N.Y.)|July 13, 2019
Boosting engineered T cellsNathan Singh, Carl H June
The Lancet. Oncology|November 8, 2016
Vemurafenib for BRAF<sup>V600E</sup>-positive metastatic papillary thyroid cancer - Authors' responseMarcia S Brose, Nathan Singh
Pageof 6